Latest news with #AlterG
Yahoo
04-06-2025
- Business
- Yahoo
Angels Receive Mike Trout News Before Dodgers Game
Nearly two months into the season, the Los Angeles Angels are 17-25 and are the only team in the AL Central with a losing record. Furthermore, they own the third-worst record in the AL and are 4-6 in their last 10 games. Los Angeles has won just one series in the month of May, and they have won two consecutive games just two times since the beginning of April. The season is still young, and they have plenty of time to turn things around. However, they will have a difficult challenge immediately in front of them. Advertisement On Friday night, they will begin a three-game series against the reigning champion Los Angeles Dodgers. The Dodgers own the best record in the NL and won three of their last four games. Los Angeles Angels outfielder Mike Trout (27)Troy Taormina-Imagn Images Once the best player in the MLB, it seems that Trout's best days could be behind him as he has struggled to stay healthy over the past few seasons. The three-time MVP has appeared in over 100 games in just one season since 2020, and his season ended after just 29 games last year. Trout is currently rehabbing a bone bruise in his knee and has been out of action since April 30. According to Angels beat writer Jeff Fletcher, however, the Angels outfielder is progressing in his recovery. Advertisement "Mike Trout has begun hitting off a machine," Fletcher wrote on X. "He's also throwing and doing agility on the field. He's running on the Alter G at 75% of his weight." Though his recovery seems to be going well, there is still no concrete timetable for Trout's return from injury. Until there is more clarity, his status will be crucial to monitor. Related: Calls Mount for Arte Moreno to Sell Angels After Shohei Ohtani News Related: Angels Predicted to Make Trade After Season-Ending Announcement
Time of India
17-05-2025
- Sport
- Time of India
Dodgers' Tommy Edman could be back soon, Teoscar Hernandez continues his recovery ahead of three-game series against Angels
The Los Angeles Dodgers prepare for a three-game series against the Los Angeles Angels during Rivalry Weekend, trying to stay on top in the NL West. The team had to face difficulties, as some important players were injured recently, but now some of them are getting better and might return soon. Tired of too many ads? go ad free now Dodgers share an update about two key players Two players the Dodgers are watching closely for injuries are Tommy Edman and Teoscar Hernandez, who are both key to the team's success. While reports suggest that Hernandez will continue the rehab, Edman might make a comeback very soon. Well, there is some good news for the Dodgers. Tommy Edman is close to returning after missing games since April 29 because of an ankle injury. The team manager Dave Roberts stated that Edman is expected to be back on Sunday during the last game of their series against the Angels. Meanwhile, Teoscar Hernandez will need some more time and will go on a rehab assignment before he can return to the team. His return will bring questions to rookie second baseman Hyeseong Kim, however. Roberts also told the press that he isn't sure what's going to happen with Hyeseong Kim once Tommy Edman returns. He said: "You can argue that Hyeseong [Kim] should be playing six or seven days a week... I just can't foresee, right now, what moves are going to be made in the coming days. I'm not sure yet.' How has Angels' Mike Trout been dealing with his injuries? Meanwhile, the Los Angeles Dodgers will be playing against the Los Angeles Angels, who have had a tough start to the season with a 17-25 record. They are the only team in the AL Central with more losses than wins and have only won one series in May. They've only won two games in a row twice since April. They'll face a big challenge starting Friday, playing a three-game series against the strong Los Angeles Dodgers, who have the best record in the National League. Tired of too many ads? go ad free now Their player Mike Trout, who was once considered the best in baseball, has struggled with injuries in recent years. He played only 29 games last season and hasn't stayed healthy for a full season since 2020. He is currently recovering from a knee injury but is slowly making progress. As per journalist Jeff Fletcher: "Mike Trout has begun hitting off a machine, He's also throwing and doing agility on the field. He's running on the Alter G at 75% of his weight." Also Read: Mike Trout seems to be healing well, but there's no clear date yet for when he will return to play. His recovery is important, so fans and the team will need to keep a close watch on his progress.
Yahoo
08-03-2025
- Business
- Yahoo
Lifeward Ltd (LFWD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Q4 2024 Revenue: $7.5 million, up from $6.9 million in Q4 2023. Full Year 2024 Revenue: $25.7 million, an 85% increase from 2023. AlterG Product Revenue: $5.5 million in Q4 2024, highest since acquisition in August 2023. ReWalk Product Revenue: $2.0 million in Q4 2024. Gross Margin (GAAP): 24.4% in Q4 2024, down from 35.5% in Q4 2023. Adjusted Gross Margin (Non-GAAP): 45.4% in Q4 2024, compared to 46.9% in Q4 2023. Operating Expenses (GAAP): $17.1 million in Q4 2024, up from $8.6 million in Q4 2023. Adjusted Operating Expenses (Non-GAAP): $6.7 million in Q4 2024, down from $7.0 million in Q4 2023. Operating Loss (GAAP): $15.2 million in Q4 2024, compared to $6.7 million in Q4 2023. Adjusted Operating Loss (Non-GAAP): $3.3 million in Q4 2024, improved from $3.8 million in Q4 2023. Cash and Equivalents: $6.7 million at year-end 2024, with no debt. 2025 Revenue Guidance: $28 million to $30 million. 2025 Adjusted Gross Margin Guidance: 47% to 49%. 2025 Non-GAAP Operating Expenses Guidance: $22 million to $23 million. 2025 Non-GAAP Operating Loss Guidance: $7 million to $9 million. Warning! GuruFocus has detected 6 Warning Signs with LFWD. Release Date: March 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lifeward Ltd (NASDAQ:LFWD) achieved record revenue of $7.5 million in Q4 2024, marking the highest quarterly revenue in the company's history. The company reported an 85% increase in full-year revenue for 2024, reaching $25.7 million, demonstrating significant business scaling. Lifeward Ltd (NASDAQ:LFWD) has established a Sustainable Growth Plan aimed at reducing costs and improving operating efficiency. The company has expanded its distribution agreement with MYOLYN, allowing for greater market penetration, particularly in the home market. Lifeward Ltd (NASDAQ:LFWD) has secured a meaningful contract with BARMER in Germany, setting a standard for providing exoskeletons. The ReWalk sales were below expectations due to delays and attrition in Medicare cases, impacting revenue predictability. GAAP gross margin decreased to 24.4% in Q4 2024 from 35.5% in Q4 2023, primarily due to restructuring charges. The company recorded a $9.8 million impairment charge on intangible assets, affecting GAAP operating expenses. Lifeward Ltd (NASDAQ:LFWD) received a going concern qualification from auditors, reflecting concerns about the adequacy of its balance sheet. The company experienced patient attrition and deferrals in the ReWalk product line, affecting sales cycles and revenue. Q: For the 2025 guidance, how do you see the growth of each component? Is the guidance generally more conservative? A: Mike Lawless, CFO: The guidance reflects growth across our three major product lines: ReWalk, AlterG, and MyoCycles. MyoCycles, being the smallest contributor, will likely show the biggest percentage growth due to an expanded distribution agreement. We expect growth in all three lines, focusing on more profitable and efficient growth. Q: What impact will the CoreLife partnership have on the workers' compensation segment? A: Larry Jasinski, CEO: The CoreLife partnership provides us with a larger conduit into the workers' compensation market, which is about 6% of all spinal cord injuries. CoreLife can process these efficiently, reducing our expenses and ensuring timely payments. Q: Will the next-gen ReWalk be introduced this year? A: Larry Jasinski, CEO: Yes, we anticipate the next-gen ReWalk will be on the market this year. The product has completed all testing, and we expect FDA clearance in the first half of the year. Q: How much of the recent announcements, like CoreLife and MyoCycle, are factored into the revenue guidance? A: Larry Jasinski, CEO: We have factored them in conservatively. CoreLife is a new arrangement, but it has good growth potential. The expanded MyoCycle agreement allows us to sell directly to home users, which is a larger market. Q: What are the learnings from the Medicare reimbursement cycle, and how does it affect discussions with private payers? A: Mike Lawless, CFO: The Medicare cycle has been longer than expected, but it provides a baseline for private payers. We anticipate CMS will become more efficient, and the commercial side seems to have a shorter path. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
